Physician profile
Sree Lakshmi Gogineni
NPI 1386603736
$4,197.96
in general payments reported to CMS, 2019-2025
20 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $614 · 2023: $748 · 2024: $1,193 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.59 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,574.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $574.17 | 2022-2025 | |
| Lilly USA, LLC | $484.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $320.84 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $250.84 | 2022-2025 | Esprit, Freestyle Libre 3 |
| Astellas Pharma US INC | $154.74 | 2023-2025 | Veozah, Myrbetriq |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Astrazeneca Pharmaceuticals Lp | $117.71 | 2023-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.62 | 2023-2025 | Jardiance |
| Kvk-Tech, INC. | $83.73 | 2024 | |
| Exact Sciences Corporation | $59.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $50.38 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.91 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $47.81 | 2023 | |
| Pfizer INC. | $46.18 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.53 | 2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $43.52 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $41.65 | 2025 | |
| Sumitomo Pharma America, INC. | $15.67 | 2025 | Gemtesa |
| Boston Scientific Corporation | $14.81 | 2025 | General - Pain Management |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sree Gogineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.